Literature DB >> 20149792

Imatinib has a fatal impact on morphology, pairing stability and survival of adult Schistosoma mansoni in vitro.

S Beckmann1, C G Grevelding.   

Abstract

Schistosomes cause bilharzia (schistosomiasis), one of the most prevalent parasitic diseases for human and animals worldwide. Praziquantel (PZQ) is the only widely used drug for treatment and control of this parasitemia. Since a vaccine is not yet available, and in light of emerging resistance against PZQ, the search for alternatives has high priority. Here we present that Imatinib, a compound used in human cancer therapy (Gleevec; STI-571), significantly affected schistosome morphology and physiology in vitro. Besides its negative effect on gonad development and pairing stability, Imatinib led to pathological alterations of the gastrodermis, which finally caused the death of the parasite. 2010 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20149792     DOI: 10.1016/j.ijpara.2010.01.007

Source DB:  PubMed          Journal:  Int J Parasitol        ISSN: 0020-7519            Impact factor:   3.981


  34 in total

1.  Characterization of the Src/Abl hybrid kinase SmTK6 of Schistosoma mansoni.

Authors:  Svenja Beckmann; Steffen Hahnel; Katia Cailliau; Mathieu Vanderstraete; Edith Browaeys; Colette Dissous; Christoph G Grevelding
Journal:  J Biol Chem       Date:  2011-10-19       Impact factor: 5.157

2.  Sorafenib and praziquantel synergistically attenuate Schistosoma japonicum-induced liver fibrosis in mice.

Authors:  Zhiyong Ma; Xia Liu; Huifen Dong; Dong Xia; Lixia Wang; Yu Chen; Yong Xiong
Journal:  Parasitol Res       Date:  2018-06-27       Impact factor: 2.289

3.  Function of Nanos1 gene in the development of reproductive organs of Schistosoma japonicum.

Authors:  Quan Liu; Lulu Zhu; Fengchun Liu; Mengqing Hua; Han Ding; Siyu He; Cuiping Ren; Miao Liu; Jijia Shen
Journal:  Parasitol Res       Date:  2017-03-28       Impact factor: 2.289

4.  The ABL kinase inhibitor imatinib causes phenotypic changes and lethality in adult Schistosoma japonicum.

Authors:  Xuesong Li; Simone Haeberlein; Lu Zhao; Mudassar N Mughal; Tao Zhu; Lu Liu; Rui Fang; Yanqin Zhou; Junlong Zhao; Christoph G Grevelding; Min Hu
Journal:  Parasitol Res       Date:  2019-02-07       Impact factor: 2.289

5.  Quantitative screening for anticestode drugs based on changes in baseline enzyme secretion by Taenia crassiceps.

Authors:  Siddhartha Mahanty; Elise M Madrid; Theodore E Nash
Journal:  Antimicrob Agents Chemother       Date:  2012-12-10       Impact factor: 5.191

6.  Targeting Filarial Abl-like Kinases: Orally Available, Food and Drug Administration-Approved Tyrosine Kinase Inhibitors Are Microfilaricidal and Macrofilaricidal.

Authors:  Elise M O'Connell; Sasisekhar Bennuru; Cathy Steel; Michael A Dolan; Thomas B Nutman
Journal:  J Infect Dis       Date:  2015-02-05       Impact factor: 5.226

7.  Eukaryotic protein kinases (ePKs) of the helminth parasite Schistosoma mansoni.

Authors:  Luiza F Andrade; Laila A Nahum; Lívia G A Avelar; Larissa L Silva; Adhemar Zerlotini; Jerônimo C Ruiz; Guilherme Oliveira
Journal:  BMC Genomics       Date:  2011-05-06       Impact factor: 3.969

Review 8.  Protein Kinases: Potential Drug Targets Against Schistosoma japonicum.

Authors:  Kaijuan Wu; Xingyu Zhai; Shuaiqin Huang; Liping Jiang; Zheng Yu; Jing Huang
Journal:  Front Cell Infect Microbiol       Date:  2021-07-01       Impact factor: 5.293

9.  Discovery of platyhelminth-specific α/β-integrin families and evidence for their role in reproduction in Schistosoma mansoni.

Authors:  Svenja Beckmann; Thomas Quack; Colette Dissous; Katia Cailliau; Gabriele Lang; Christoph G Grevelding
Journal:  PLoS One       Date:  2012-12-27       Impact factor: 3.240

10.  Dual targeting of insulin and venus kinase Receptors of Schistosoma mansoni for novel anti-schistosome therapy.

Authors:  Mathieu Vanderstraete; Nadège Gouignard; Katia Cailliau; Marion Morel; Julien Lancelot; Jean-François Bodart; Colette Dissous
Journal:  PLoS Negl Trop Dis       Date:  2013-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.